Therapy News and Research

RSS

Healthy older adults without sleep disorders may need less sleep

A study in the Feb. 1 issue of the journal SLEEP suggests that healthy older adults without sleep disorders can expect to have a reduced "sleep need" and to be less sleepy during the day than healthy young adults.

1 Feb 2010

Study assesses gray matter concentration deficits in multiple brain areas of people with OSA

A study in the Feb. 1 issue of the journal SLEEP found gray matter concentration deficits in multiple brain areas of people with severe obstructive sleep apnea (OSA). The study suggests that the memory impairment, cardiovascular disturbances, executive dysfunctions, and dysregulation of autonomic and respiratory control frequently observed in OSA patients may be related to morphological changes in brain structure.

1 Feb 2010

Study indicates dogs make excellent models for studying human genetic disorders

In the new Swedish-Finnish study, published in Nature Genetics, the researchers identified five loci that predispose to an SLE-related disease in Nova Scotia duck tolling retrievers.

31 Jan 2010

U.S. Marshals seize unapproved ozone generators from Applied Ozone Systems

At the request of the U.S. Food and Drug Administration, U.S. Marshals today seized 79 ozone generators, models AOS-1M and AOS-1MD, from Applied Ozone Systems of Auburn, Calif. The seized goods, which are medical devices, are valued at $75,900.

30 Jan 2010

AAPM reassures safety of radiation therapy

The American Association of Physicists in Medicine (AAPM) has issued a statement today in the wake of several recent articles in the New York Times yesterday and earlier in the week that discuss a number of rare but tragic events in the last decade involving people undergoing radiation therapy.

30 Jan 2010

Redwood Consultants to assist DMI Life Sciences in shareholder relations and investor communications

DMI Life Sciences, Inc., which recently announced that it has entered into a non-binding letter of intent with Imagine Media, Ltd. is pleased to announce today that the Company has retained California-based Redwood Consultants, LLC to assist in shareholder relations and investor communications.

30 Jan 2010

New biomarker may predict treatment outcomes in RA patients

Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.

30 Jan 2010

Prime Therapeutics receives full accreditation from URAC Accreditation Committee for PrimeMail

Prime Therapeutics LLC (Prime), a thought leader in pharmacy benefit management, announced today that it has received full accreditation from the URAC Accreditation Committee for its mail-service pharmacy, PrimeMail®.

30 Jan 2010

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

30 Jan 2010

Study shows majority of patients gain weight after knee replacement surgery

You'd think folks who've had knee replacement surgery -- finally able to walk and exercise without pain -- would lose weight instead of put on pounds, but surprisingly that's not the case, according to a University of Delaware study.

30 Jan 2010

$Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia$

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of perifosine (KRX-0401) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of the Journal of Clinical Cancer Research.

30 Jan 2010

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

Houston Technology Center (HTC), announced today that client company Salient Pharmaceuticals received a $2 million commercialization award from the Texas Emerging Technology Fund (TETF) for the commercialization of their CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.

29 Jan 2010

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.

29 Jan 2010

New mathematical model helps in predicting treatment outcomes for cervical cancer patients

Cervical cancer is highly curable when caught early. But in a third of cases, the tumor responds poorly to therapy or recurs later, when cure is much less likely.

29 Jan 2010

GlaxoSmithKline's Lamictal XR Extended-Release Tablets receive FDA approval

laxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal®XR™ (lamotrigine) Extended-Release Tablets as once-a-day, add-on therapy for epilepsy in patients ages 13 years and older with primary generalized tonic-clonic seizures.

29 Jan 2010

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.

29 Jan 2010

LinkMed’s portfolio company receives order from Siemens AG for DIGNITY Carrier

LinkMed’s portfolio company has received an order from Siemens AG, Health Care Sector, Germany for its patient transportation solution, DIGNITY™ Carrier, for setting up patients for PET/CT imaging for special applications.

29 Jan 2010

ECCO supports its member organisations' proposals for adapting the EU Clinical Trials Directive

In response to a European Commission consultation on the EU Clinical Trials Directive, ECCO - the European CanCer Organisation - has supported proposals by its member organisations for adapting the Directive's requirements to reflect practical necessities in cancer research and treatment.

29 Jan 2010

ChromoCure retains Patent & Intellectual Property Attorneys to assess its Intellectual Property portfolio

ChromoCure, Inc. -- The Company announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections.

29 Jan 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

Therapy News and Research

Healthy older adults without sleep disorders may need less sleep

Study assesses gray matter concentration deficits in multiple brain areas of people with OSA

Study indicates dogs make excellent models for studying human genetic disorders

U.S. Marshals seize unapproved ozone generators from Applied Ozone Systems

AAPM reassures safety of radiation therapy

Redwood Consultants to assist DMI Life Sciences in shareholder relations and investor communications

New biomarker may predict treatment outcomes in RA patients

Prime Therapeutics receives full accreditation from URAC Accreditation Committee for PrimeMail

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

Study shows majority of patients gain weight after knee replacement surgery

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Salient Pharmaceuticals receives TETF commercialization award for CASAD therapy commercialization

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

New mathematical model helps in predicting treatment outcomes for cervical cancer patients

GlaxoSmithKline's Lamictal XR Extended-Release Tablets receive FDA approval

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

LinkMed’s portfolio company receives order from Siemens AG for DIGNITY Carrier

ECCO supports its member organisations' proposals for adapting the EU Clinical Trials Directive

ChromoCure retains Patent & Intellectual Property Attorneys to assess its Intellectual Property portfolio

Global market for oncology drugs is forecast to reach $80 billion by 2050

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News